Boothbay Fund Management, LLC Mirati Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

  • $3.6 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$41.99 - $62.38 $419,900 - $623,800
10,000 New
10,000 $587,000
Q1 2023

May 15, 2023
SELL
$36.54 - $54.26 $513,021 - $761,810
-14,040 Reduced 69.38%
6,196 $230,000
Q4 2022

Feb 14, 2023
BUY
$41.27 - $98.62 $835,139 - $2 Million
20,236 New
20,236 $916,000
Q4 2020

Feb 12, 2021
SELL
$162.05 - $240.27 $658,895 - $976,937
-4,066 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$113.26 - $167.27 $460,515 - $680,119
4,066 New
4,066 $675,000

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email